Evotec (EVO) Stock: Buy, Sell, or Hold?
EVO - Evotec SE American Depositary Shares
$1.60
-0.04 (-2.74%)
▼
5d:
+2.56%
30d:
-15.79%
90d:
-45.21%
HOLD
LOW Confidence
Analysis Updated: Oct 2, 2026 12:00 AM ET
Earnings: May 06, 2026
0d
Get Alerted When EVO Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 HOLD: EVO shows mixed signals. Fine to hold existing positions. Not urgent to buy or sell.
📊 HOLD: EVO shows mixed signals. Fine to hold existing positions. Not urgent to buy or sell.
In-depth Analysis How we analyze
Valuation Analysis: EVO is currently trading at $1.60, which is considered slightly low relative to its 30-day fair value range of $1.58 to $1.86. From a valuation perspective, the stock is trading at a discount (Forward PE: 22.9) compared to its historical average (29.6). Remarkably, the market is currently pricing in an annual earnings decline of 8.3% over the next few years. This aligns with recent fundamental challenges.
Technical Outlook: Technically, EVO is in a strong downtrend. Immediate support is located at $1.50, while resistance sits at $1.71.
Market Sentiment: EVO scores 75/100 on our bottoming-setup gauge — the chart has corrected and is stabilizing (RSI reset, momentum turning up), historically a favorable entry zone. Wall Street analysts see significant upside, with an average price target of $4.18 (+161.0%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Technical Outlook: Technically, EVO is in a strong downtrend. Immediate support is located at $1.50, while resistance sits at $1.71.
Market Sentiment: EVO scores 75/100 on our bottoming-setup gauge — the chart has corrected and is stabilizing (RSI reset, momentum turning up), historically a favorable entry zone. Wall Street analysts see significant upside, with an average price target of $4.18 (+161.0%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Quick Decision Summary
Current Position
SLIGHTLY LOW
Historical Trading Range
$1.58 -
$1.86
Company Quality Score
55/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
90.5%
All Signals
- BULLISH: Price oversold vs 30-day range
- BULLISH: Strong technical setup (75/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 161.0% below Wall St target ($4.18)
- CAUTION: Bottoming setup, but lagging the sector by 30% over 20 days — wait for relative strength
Trading Range Analysis
30-Day Trading Range
$1.58 -
$1.86
Current vs Trading Range
SLIGHTLY LOW
Support & Resistance Levels
Support Level
$1.50
Resistance Level
$1.71
Current Trend
Strong Downtrend
Technical data as of
Oct 2, 2026
Fundamental Context
Forward P/E (Next Year Est.)
22.86
Wall Street Target
$4.18
(+161.0%)
Revenue Growth (YoY)
-16.2%
Profit Margin
-27.5%
Valuation Discount vs History
-8.3% cheaper
PE vs Historical
22.9 vs 29.6
CHEAP
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
-8.3%
(market-implied from PE analysis)
1-Year Target
$1.47
(-8%)
2-Year Target
$1.35
(-16%)
3-Year Target
$1.23
(-23%)
3-Yr Target (if PE normalizes)
(PE: 23→30)
$1.60
(0%)
💡
Upside Surprise Potential
If earnings stabilize (0% growth), PE could expand from 22.9 to 29.6
Stabilization Target:
$2.07
(+29.5%)
PE Expansion Potential:
+29.5%
Share & Embed Analysis
Last updated: October 04, 2026 5:59 AM ET
Data refreshes hourly during market hours. Next update: 6:59 AM
Data refreshes hourly during market hours. Next update: 6:59 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is EVO showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Drug Manufacturers - Specialty & Generic Stocks
Top-rated stocks in Drug Manufacturers - Specialty & Generic by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
NBIX
Neurocrine Biosciences I… |
STRONG BUY
25 analysts |
$208 | 62 BUY |
|
ZTS
Zoetis Inc |
BUY
20 analysts |
$96 | 58 HOLD |
|
LNTH
Lantheus Holdings Inc |
STRONG BUY
13 analysts |
$108 | 56 HOLD |
|
AQST
Aquestive Therapeutics I… |
STRONG BUY
9 analysts |
$9 | 67 BUY |
|
BCRX
BioCryst Pharmaceuticals… |
STRONG BUY
12 analysts |
$21 | 47 HOLD |
